| Cai, Wei |
| Recruiting | N/A | 100 | RoW | Prebiotic fructans, Non-prebiotic maltodextrin | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Beneo GmbH | Constipation | 12/22 | 12/22 | | |
NCT05476289: A Follow-up Study of Dragon Study (NCT03520764): to Assess the Growth and Immune-related Outcomes |
|
|
| Completed | N/A | 226 | RoW | No intervention | Danone Nutricia, Nutricia Early Life Nutrition (Shanghai) Co., Ltd | Healthy Nutrition | 11/21 | 11/23 | | |
| Recruiting | N/A | 262 | RoW | Experimental Group (EG), Control Group (CG) | Société des Produits Nestlé (SPN) | Healthy Infants | 11/26 | 06/27 | | |
NCT06644274: The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Gastrointestinal Malignancies |
|
|
| Recruiting | N/A | 40 | RoW | | Ruijin Hospital | Gastrointestinal Malignancies | 06/26 | 07/27 | | |
| Recruiting | N/A | 326 | RoW | New infant formula with 6 HMOs blend, Standard infant formula without 6 HMOs blend | Junlebao Dairy Group Co., Ltd., Merieux NutriSciences (China) | Healthy Infants | 04/27 | 04/27 | | |
NCT00289380: Nutrition Support on Outcomes and Cost-effectiveness for Patients at Risk |
|
|
| Recruiting | N/A | 2000 | RoW | | Peking Union Medical College | Malnutrition, Nutritional Risk | 01/40 | 01/40 | | |
| Lu, Wei |
UplighTED, NCT06307626: A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults with Thyroid Eye Disease. |
|
|
| Recruiting | 3 | 108 | Europe, Japan, US, RoW | Efgartigimod PH20 SC, Placebo PH20 SC | argenx | Thyroid Eye Disease | 02/26 | 10/27 | | |
NCT05251662: Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 90 | RoW | Sintilimab, IBI305, Bevacizumab Biosimilar, GEMOX | Tianjin Medical University Cancer Institute and Hospital | Intrahepatic Cholangiocarcinoma | 01/24 | 01/25 | | |
NCT05651672: Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations |
|
|
| Recruiting | 2 | 100 | RoW | Pemigatinib, Pemazyre | Tianjin Medical University Cancer Institute and Hospital | Gastrointestinal Cancer | 12/24 | 12/26 | | |
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2 | 162 | RoW | BAT4406F Injection, BAT4406F Placebos | Bio-Thera Solutions | Optic Neuromyelitis Spectrum Disease | 05/25 | 05/26 | | |
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 70 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Intrahepatic Cholangiocarcinoma (ICC) | 05/26 | 12/26 | | |
NCT06310590: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 40 | RoW | NRT6003 Injection, Yttrium-90 carbon microspheres | Chengdu New Radiomedicine Technology Co. LTD. | Unresectable Hepatocellular Carcinoma | 10/25 | 10/25 | | |
NCT05776121: Study of ZB001 in Chinese Patients With Thyroid Eye Disease |
|
|
| Active, not recruiting | 1 | 17 | RoW | ZB001 for injection | Zenas BioPharma (USA), LLC | Thyroid Eye Disease | 10/24 | 10/24 | | |
NCT06047431: A Study of QL1706H in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 150 | NA | QL1706H | Qilu Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/24 | 12/25 | | |
| Recruiting | N/A | 120 | RoW | early APM, Early arthroscopic partial meniscectomy, delayed APM, delayed arthroscopic partial meniscectomy | The First People's Hospital of Jingzhou | Meniscus Tear | 12/22 | 12/22 | | |
NCT05711459: Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury. |
|
|
| Recruiting | N/A | 5405 | RoW | Bicyclol tablets | Tianjin Medical University Cancer Institute and Hospital | Drug-Induced Acute Liver Injury | 05/23 | 05/24 | | |
NCT05215665: GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma |
|
|
| Recruiting | N/A | 146 | RoW | GEMOX Regimen, Lenvatinib, Toripalimab | Tianjin Medical University Cancer Institute and Hospital | Cholangiocarcinoma | 05/24 | 01/26 | | |
NCT06292715: Microwave Ablation With Splenic Artery Occlusion for Secondary Hypersplenism |
|
|
| Recruiting | N/A | 35 | RoW | microwave ablation of the spleen, Splenic artery balloon implantation | Tianjin Medical University Cancer Institute and Hospital | Secondary Hypersplenism | 12/25 | 12/26 | | |
NCT05791604: The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics |
|
|
| Recruiting | N/A | 60 | RoW | probiotics including B. lactis B420, B. lactis HN019, B. animalis Bb-12, L. rhamnosus GG, Prebiotics with galactomannan and oligofructose | Children's Hospital of Fudan University | Prader-Willi Syndrome | 03/26 | 07/26 | | |
| Li, Yufeng |
NCT05102149: Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus |
|
|
| Recruiting | 3 | 672 | RoW | PB-201, Vildagliptin, PB-201 matched placebo, Vildagliptin matched placebo | PegBio Co., Ltd. | Type 2 Diabetes Mellitus (T2DM) | 11/23 | 04/25 | | |
NCT06350890: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 408 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | T2DM (Type 2 Diabetes Mellitus) | 03/25 | 09/25 | | |
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 551 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | Type 2 Diabetes Mellitus | 03/25 | 12/25 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
NCT05352516 / 2022-002188-31: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture |
|
|
| Completed | 3 | 514 | RoW | HLX14, Prolia® | Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc. | Postmenopausal | 12/23 | 07/24 | | |
| Completed | 3 | 257 | RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases | 07/24 | 07/24 | | |
NCT06696261: A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome |
|
|
| Not yet recruiting | 3 | 342 | RoW | Lianxiaxiaopi Granules, a simulated agent of Lianxiaxiaopi Granules | Tasly Pharmaceutical Group Co., Ltd | Postprandial Distress Syndrome | 06/26 | 08/26 | | |
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone |
|
|
| Active, not recruiting | 3 | 520 | Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Type 2 Diabetes | 04/25 | 04/25 | | |
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 1576 | Japan, US, RoW | Orforglipron, LY3502970, Semaglutide | Eli Lilly and Company | Type 2 Diabetes | 09/25 | 09/25 | | |
NCT05850546: Rituximab in the First Episode of Paediatric Nephrotic Syndrome |
|
|
| Not yet recruiting | 3 | 138 | RoW | Rituximab, rituximab biosimilar (HANLIKANG®, Shanghai Henlius Biotech, Inc. China), Corticosteroid, prednisolone/prednisone | Children's Hospital of Fudan University, Shanghai Shen Kang Hospital Development Center, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Children's Medical Center, Shanghai Children's Hospital | Steroid-Sensitive Nephrotic Syndrome | 05/26 | 09/26 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT05227677: Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 200 | RoW | GA guided anti-diabetic therapy adjustment, current guidelines to adjust treatment | Asahi Kasei Pharma Corporation | Type 2 Diabetes Mellitus | 08/24 | 12/24 | | |
NCT04588025: Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response |
|
|
| Recruiting | N/A | 55 | US | Point-of-care Portable Perfusion Phantom, P4 | University of Alabama at Birmingham | Pancreatic Cancer | 10/25 | 10/26 | | |
NCT05866029: Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture |
|
|
| Recruiting | N/A | 2478 | RoW | Denosumab, Teriparatide | Peking Union Medical College Hospital | Osteoporotic Fractures | 09/26 | 09/26 | | |
| Wang, Ying |
NCT05071482: Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL |
|
|
| Recruiting | 4 | 238 | RoW | Flumatinib, Imatinib | wang, jianxiang | Acute Leukemia | 10/25 | 10/25 | | |
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 |
|
|
| Recruiting | 3 | 366 | RoW | RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda | RemeGen Co., Ltd. | Breast Cancer | 06/24 | 12/24 | | |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 551 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | Type 2 Diabetes Mellitus | 03/25 | 12/25 | | |
MELATORCH, NCT03430297: A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma |
|
|
| Completed | 3 | 256 | RoW | JS001 240mg Q2W, Dacarbazine 1000mg/m2 Q3W | Shanghai Junshi Bioscience Co., Ltd. | Metastatic Melanoma, Unresectable Melanoma | 07/23 | 11/23 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
NCT06051409: A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. |
|
|
| Recruiting | 3 | 350 | RoW | Olverembatinib, Imatinib | Ascentage Pharma Group Inc., HealthQuest Pharma Inc. | Ph+ ALL | 12/24 | 10/28 | | |
NCT06738979: A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects |
|
|
| Not yet recruiting | 3 | 408 | RoW | TQF3510 (Semaglutide Injection), Wegovy® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Obesity | 07/26 | 08/26 | | |
DIAMOND, NCT04907370: PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 3 | 540 | RoW | PD-1 blocking antibody, PD-1 Blockade, Gemcitabine, GEM, Cisplatin (80mg/m2), DDP, Cisplatin (100mg/m2), Intensity-modulated radiotherapy, IMRT | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd. | Nasopharyngeal Carcinoma | 05/25 | 05/27 | | |
NCT05780372: Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 474 | RoW | Intensity Modulated Radiation Therapy, IMRT, Chemotherapy | Sun Yat-sen University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Chongqing University Cancer Hospital, Dongguan People's Hospital, LiuZhou People's Hospital | Nasopharyngeal Carcinoma, Radiotherapy; Complications | 05/25 | 05/28 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
NCT05904964: Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial) |
|
|
| Recruiting | 3 | 288 | RoW | Disitamab vedotin, RC48, Endocrine therapy | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | HR Positive/HER2 Low Expression Metastatic Breast Cancer | 03/28 | 03/30 | | |
NCT04646759: Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 516 | RoW | Fulvestrant combined with Pyrotinib, FASLODEX combined with Pyrotinib, Capecitabine combined with Pyrotinib, xeloda combined with Pyrotinib | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 12/28 | 12/30 | | |
NCT06083623: A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants |
|
|
| Not yet recruiting | 2b | 2250 | RoW | TNM001, placebo | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Respiratory Syncytial Virus Infections | 05/26 | 08/26 | | |
2019-KY-049, NCT04034589: Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer |
|
|
| Recruiting | 2 | 46 | RoW | Pyrotinib combined with fulvestrant | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Metastatic Breast Cancer | 07/21 | 07/22 | | |
NCT06429098: Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML |
|
|
| Recruiting | 2 | 40 | RoW | Venetoclax, ABT-199, ABT199, Venclexta, azacitidine, 5 AZC, 5-AZC, decitabine, Dacogen, Cytarabine, 1-.beta.-Cytosine arabinoside, Ara-C | The First Affiliated Hospital of Soochow University | Acute Myeloid Leukemia | 06/27 | 12/27 | | |
NCT04905550: Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC |
|
|
| Recruiting | 2 | 50 | RoW | Almonertinib, The third generation of EGFR - TKI, Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT) | Chongqing University Cancer Hospital | Non-Small Cell Lung Cancer (NSCLC) | 03/24 | 08/24 | | |
NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC |
|
|
| Recruiting | 2 | 60 | RoW | HLX07+HLX10+ Cisplatin+5-FU, HLX07 | Shanghai Henlius Biotech | ESCC or Esophageal Adenosquamous Carcinoma | 06/24 | 08/25 | | |
| Recruiting | 2 | 39 | RoW | Camrelizumab, Anti-PD-1 antibody, Stereotactic body radiotherapy, SBRT | Chongqing University Cancer Hospital | Nasopharyngeal Carcinoma | 08/24 | 08/26 | | |
| Recruiting | 2 | 22 | RoW | Anti-CD7 CAR-T | Ying Wang | Hematological Malignancies | 09/24 | 09/25 | | |
| Recruiting | 2 | 60 | RoW | Olverembatinib, Venetoclax, prednisone, Vincristine | Institute of Hematology & Blood Diseases Hospital, China | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | 10/24 | 03/25 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
NCT05660473: Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 2 | 100 | RoW | Vincristine, Daunorubicin, Cyclophosphamide, Pegaspargase, Prednisone, Cytarabine, 6-mercaptopurine, Dexamethasone, Methotrexate, Venetoclax | Institute of Hematology & Blood Diseases Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12/24 | 12/27 | | |
NCT05213884: The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC |
|
|
| Recruiting | 2 | 30 | RoW | Camrelizumab, Anti-PD-1 antibody, Concurrent cisplatin chemotherapy, Intensity-modulated radiotherapy (IMRT) | Chongqing University Cancer Hospital | Head and Neck Squamous Cell Carcinoma | 01/25 | 01/27 | | |
NCT06059261: Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. |
|
|
| Recruiting | 2 | 45 | RoW | Envafolimab and recombinant human endostatin combined with chemoradiotherapy | Chongqing University Cancer Hospital, Fujian Cancer Hospital, Sun Yat-sen University | Nasopharyngeal Carcinoma | 10/27 | 10/27 | | |
NCT06776757: Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer |
|
|
| Recruiting | 1/2 | 30 | RoW | Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI) | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | Metastatic Colorectal Cancer | 06/25 | 12/25 | | |
| Recruiting | 1/2 | 203 | RoW | CN201, CN201 for Injection | Curon Biopharmaceutical (Shanghai) Co.,Ltd | Acute Lymphoblastic Leukemia | 05/25 | 07/25 | | |
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors |
|
|
| Recruiting | 1/2 | 133 | RoW | KC1036 | Beijing Konruns Pharmaceutical Co., Ltd. | Digestive System Tumors | 10/25 | 12/25 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT06536400: Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation |
|
|
| Recruiting | 1 | 316 | RoW | HSK42360 | Haisco Pharmaceutical Group Co., Ltd. | Solid Tumors | 08/26 | 07/27 | | |
NCT06608329: A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 33 | RoW | HDM1002 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Healthy Adult Subject | 11/24 | 12/24 | | |
NCT05473624: Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 153 | RoW | HRS-1167 | Jiangsu HengRui Medicine Co., Ltd. | Advanced Solid Tumors | 12/24 | 12/24 | | |
NCT05360043: Efficacy and Safety of 1565-nm Non-ablative Fractional Laser Versus Long-pulsed 1064-nm Nd:YAG Laser in the Treatment of Enlarged Facial Pores |
|
|
| Recruiting | N/A | 27 | RoW | laser treatment | Second Affiliated Hospital, School of Medicine, Zhejiang University | Enlarged Facial Pores | 04/22 | 10/22 | | |
NCT04800575: Comparison of Sterile Gauze and Semi-permeable Film Dressing for Hemodialysis Central Venous Catheter |
|
|
| Recruiting | N/A | 154 | RoW | semi-permeable film, sterile gauze and tape | Peking University People's Hospital | Infection, Bacterial | 05/22 | 12/22 | | |
NCT04008524: A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies |
|
|
| Available | N/A | | RoW | CAR-T cells | Institute of Hematology & Blood Diseases Hospital, Juventas Cell Therapy Ltd. | Relapsed and Refractory Hematological Malignancies | | | | |
HRQoL, NCT03926858: Patient-reported Outcomes of Postsurgical Pain and Health Related Quality of Life |
|
|
| Completed | N/A | 2000 | RoW | | Peking University People's Hospital | Post Surgical Pain | 05/23 | 05/23 | | |
| Recruiting | N/A | 100 | RoW | Prebiotic fructans, Non-prebiotic maltodextrin | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Beneo GmbH | Constipation | 12/22 | 12/22 | | |
NCT04880083: Feeding Tolerance and Gut Maturation of Infants Consuming a Formula Rich in Glycoprotein |
|
|
| Completed | N/A | 120 | RoW | Commercially Available Starter Infant Formula | Société des Produits Nestlé (SPN), Medrio, Inc, SAS Institute, Veeva Systems | Digestion, Gut Microbiota | 12/22 | 12/22 | | |
| Recruiting | N/A | 100 | RoW | Automated peritoneal dialysis, Intermittent hemodialysis | Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation | Acute Kidney Injury | 12/22 | 12/22 | | |
| Recruiting | N/A | 206 | RoW | automated peritoneal dialysis, IHD | Peking Union Medical College Hospital, First Hospital of China Medical University, Beijing Anzhen Hospital, The Luhe Teaching Hospital of the Capital Medical University, Ningbo No.2 Hospital | ESRD | 12/22 | 02/23 | | |
NCT05540795: Diagnostic Accuracy of 3T MR for Secondary Hyperparathyroidism Comparison With 4DCT |
|
|
| Completed | N/A | 15 | RoW | | Fifth Affiliated Hospital, Sun Yat-Sen University | Parathyroid Gland Disease, Secondary Hyperparathyroidism | 05/23 | 07/23 | | |
NCT06167109: NBI Combined With MRI to Guide CTV Optimization in Eccentric Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 60 | RoW | CTV optimized IMRT | Chongqing University Cancer Hospital | Nasopharyngeal Carcinoma by AJCC V8 Stage | 05/26 | 10/26 | | |
NCT05014893: Neural Mechanisms of Cognitive Assessment and Rehabilitation for Cognitive Decline |
|
|
| Recruiting | N/A | 100 | RoW | multi-modal targeted intervention (e.g., cognitive training, exercise, games) | National Research Center for Rehabilitation Technical Aids, Nanjing Brain Hospital, The Third People's Hospital of Yunnan Province, Central South University, Beijing academy of science and technology, Beijing University of Chinese Medicine | Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD), Aging, Healthy | 12/26 | 12/26 | | |
NCT06511453: Acupressure in Patients With Sickle Cell Disease |
|
|
| Recruiting | N/A | 240 | US | Acupressure (using AcuWand or pencil eraser) | Indiana University, University of California, Irvine | Sickle Cell Disease | 02/29 | 08/29 | | |
NCT05992285: A Clinical Study of Theta Burst Stimulation (cTBS) in the Treatment of Insomnia Disorder Targeting the Dentate Nucleus of the Cerebellum |
|
|
| Completed | N/A | 68 | RoW | transcranial magnetic stimulation | Xijing Hospital, First Affiliated Hospital of Xi'an Medical University, Xi'an No.1 Hospital, Xi'an International Medical Center Hospital, Xi'an Hospital of Traditional Chinese Medicine | Insomnia Disorder | 10/24 | 10/24 | | |
NCT05961566: Palatal Volumetric Change Analysis Following Connective Tissue Graft With and Without Donor Site Augmentation |
|
|
| Recruiting | N/A | 40 | US | Use of collagen matrix after subepithelial connective tissue graft harvest, Helistat - collagen matrix group, Experimental | Hailey Bivens | Recession, Gingival | 09/24 | 03/25 | | |
| Recruiting | N/A | 500 | RoW | 18F-S16/T807 | Tianjin Medical University, Tianjin Medical University General Hospital | Tauopathies, Neurodegenerative Diseases, Neurodegeneration | 11/27 | 12/27 | | |
NCT06725719: Translocator Protein PET/CT in Various TSPO-Related Disease |
|
|
| Recruiting | N/A | 200 | RoW | 18F-DPA714/FDPA | Tianjin Medical University, Tianjin Medical University General Hospital | Neuroinflammation, Stroke, Neurodegenerative Diseases | 12/27 | 12/27 | | |
NCT06725706: Beta Amyloid PET/CT in Various Aβ-Related Disease |
|
|
| Recruiting | N/A | 500 | RoW | 18F-92/AV45, 11C-PIB | Tianjin Medical University, Tianjin Medical University General Hospital | Amyloid, Beta-Amyloid, Neurodegenerative Diseases | 12/27 | 12/27 | | |
NCT05483790: The Effects of Multidomain Non-pharmacological Interventions on the Elderly With or Without Mild Cognitive Impairment |
|
|
| Active, not recruiting | N/A | 112 | RoW | the multimodal intervention | Huashan Hospital, School of Public Health，Fudan University, Medicine-Mental Health Center of Minhang District, Xinzhuang Community Health Service Center | Mild Cognitive Impairment, The Cognitive Normal Elderly | 12/24 | 12/24 | | |
NCT06725550: Integrative Medicine in Pain Management in Sickle Cell Disease |
|
|
| Not yet recruiting | N/A | 120 | US | needling acupuncture, laser acupuncture | Indiana University | Sickle Cell Disease, Pain, Acupuncture, Quantitative Sensory Testing, Magnetic Resonance Imaging, Circulating Biomarkers, Electroencephalography, Functional Near-infrared Spectroscopy | 02/29 | 02/30 | | |
NCT05045820: Integrative Medicine in Pain Management in Sickle Cell Disease |
|
|
| Recruiting | N/A | 60 | US | needling acupuncture, laser acupuncture | Indiana University, National Center for Complementary and Integrative Health (NCCIH) | Sickle Cell Disease, Pain, Acupuncture, Quantitative Sensory Testing, Magnetic Resonance Imaging, Circulating Biomarkers, Electroencephalography, Functional Near-infrared Spectroscopy | 05/25 | 05/26 | | |
NCT04683757: The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer |
|
|
| Recruiting | N/A | 288 | RoW | Establishment of a Survival Prediction Model | Ying Wang | Breast Cancer | 01/21 | 12/24 | | |
NCT04683445: Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer |
|
|
| Recruiting | N/A | 80 | RoW | Eribulin, Halaven, Trastuzumab, Herceptin, pertuzumab, Perjeta, Pyrotinib, Pembrolizumab, Keytruda, Camerlizumab | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 12/22 | 12/23 | | |
| Recruiting | N/A | 1000 | RoW | Carotid revascularization, carotid endarterectomy and carotid artery stent, MRI-PWI, CTA, PET/MRI, Ultrasound | Peking Union Medical College Hospital | Carotid Artery Stenosis | 12/25 | 12/26 | | |
| Zhang, Jinsong |
| Recruiting | N/A | 100 | RoW | executive function family training, treat as usual | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | ADHD | 10/23 | 10/25 | | |
| Wang, Jiandong |
NCT05237193: A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up |
|
|
| Recruiting | N/A | 400 | RoW | The level of CIN | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Zhongshan Hospital, Ruijin Hospital, Changhai Hospital, Shanghai Changzheng Hospital, Eastern Hepatobiliary Surgery Hospital, First Affiliated Hospital Xi'an Jiaotong University, Jiangsu Provincial People's Hospital, Third Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Zhejiang University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Second Hospital of Jilin University, West China Hospital, Southwest Hospital, China, Affiliated Hospital of North Sichuan Medical College, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Biliary Tract Neoplasms, Pancreatic Carcinoma, Gallbladder Cancer, Pancreatic Head Carcinoma | 09/23 | 03/24 | | |
| Wang, Hui |
NCT05518929: Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients |
|
|
| Completed | 4 | 1090 | RoW | Ciprofol, Propofol | RenJi Hospital, Zhejiang Tumor Hospital, Beijing Hospital, Second Hospital of Shanxi Medical University, Dalian Municipal Friendship Hospital | Gastric Ulcer, Gastric Cancer, Gastrointestinal Polyp | 08/23 | 08/23 | | |
APPROACH, NCT04841811: MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model. |
|
|
| Recruiting | 3 | 192 | RoW | Almonertinib, ctDNA dynamic monitoring guided the Almonertinib treatment | Guangdong Association of Clinical Trials, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Lung Cancer | 12/24 | 12/26 | | |
| Recruiting | 3 | 315 | RoW | TQB2450, Anlotinib, TQB2450(blank), Anlotinib(blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Stage III Non-small-cell Lung Cancer | 12/22 | 03/25 | | |
| Not yet recruiting | 3 | 358 | RoW | TQB2450+Anlotinib, TQB2450 placebo + Anlotinib placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Small Cell Lung Cancer Limited Stage | 09/26 | 09/26 | | |
NCT06000956: A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo |
|
|
| Recruiting | 3 | 408 | RoW | Jitongning tablets, a simulated agent of Jitongning tablets | Tasly Pharmaceutical Group Co., Ltd | Ankylosing Spondylitis | 12/26 | 12/26 | | |
NCT05652894: A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 3 | 190 | RoW | HX008, Investigator's Choice Chemotherapy | Taizhou Hanzhong biomedical co. LTD | Metastatic Colorectal Cancer | 01/26 | 10/28 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
NCT05254665: A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 2 | 110 | RoW | Docetaxel Polymeric Micelles for Injection | Jiangsu Simcere Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/22 | 03/24 | | |
NCT04922450: Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 53 | RoW | PD-1 inhibitor, Albumin Paclitaxel, Cisplatin | Hunan Cancer Hospital, Jiangsu HengRui Medicine Co., Ltd. | Head and Neck Cancer, Squamous Cell Carcinoma | 01/23 | 01/23 | | |
